干扰素 beta-1a

[ 储存条件 ]:
-70°C

[ RTECS号 ]:
NM9701100

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.

J. Neurol. Neurosurg. Psychiatr. 84(11) , 1186-91, (2013)

To investigate the associations of serum lipid profile with disease progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event.High density lipoprotein cholestero...

Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.

Drug Des. Devel. Ther. 6 , 175-86, (2012)

Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, traditionally considered to be an autoimmune, demyelinating disease. Based on this understanding, the initial ...

Emerging injectable therapies for multiple sclerosis.

Lancet Neurol. 12(11) , 1115-26, (2013)

Available treatment options for relapsing-remitting multiple sclerosis (MS) have expanded in recent years, and several injectable therapies are under development. In this Rapid Review, we summarise em...

更多文献

暂无推荐供应商。请联系客服获知如何成为推荐供应商。